Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIPAC: IMP321 plus paclitaxel in hormone receptor-positive metastatic breast cancer
2015-002541-63Phase 2Completed
- Sponsor
- Immutep Limited
- Start
- Oct 2015
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer and breast adenocarcinoma comparing Eftilagimod alfa + paclitaxel with Placebo + paclitaxel (2 arms). Started Oct 2015; status: completed.
02
Drugs
eftilagimod alpha
03
Conditions
breast cancerbreast adenocarcinoma
Beyond the preview
Go deeper on 2015-002541-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002541-63.